Previous studies reported that several signaling pathways, including PI3K/AKT, MEK/ERK, and STAT3, are essential for survival and/or resistance to ALK inhibitors in ALK-rearranged NSCLC cells [12, 32]. Here, MAP2K7 is linked to non-small cell lung carcinoma.